<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer Milan</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22430431</article-id><article-id pub-id-type="pmc">3356470</article-id><article-id pub-id-type="publisher-id">428</article-id><article-id pub-id-type="doi">10.1007/s10194-012-0428-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The 5-HT<sub>1F</sub> receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Tfelt-Hansen</surname><given-names>Peer C.</given-names></name><address><email>ptha@glo.regionh.dk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Olesen</surname><given-names>Jes</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Neurology, Danish Headache Center, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>3</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>3</month><year>2012</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2012</year></pub-date><volume>13</volume><issue>4</issue><fpage>271</fpage><lpage>275</lpage><history><date date-type="received"><day>2</day><month>1</month><year>2012</year></date><date date-type="accepted"><day>16</day><month>2</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2012</copyright-statement></permissions><abstract id="Abs1"><p>Lasmiditan is a novel selective 5-HT<sub>1F</sub> receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT<sub>1F</sub> receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5&#x02013;45&#x000a0;mg were used, and there was a linear association between headache relief (HR) rates and dose levels (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.02). For lasmiditan 20&#x000a0;mg, HR was 64&#x000a0;% and for placebo it was 45&#x000a0;% (NS). In the oral placebo-controlled RCT, lasmiditan doses of 50, 100, 200 and 400&#x000a0;mg were used. For HR, all doses of lasmiditan were superior to placebo (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05). For lasmiditan 400&#x000a0;mg, HR was 64&#x000a0;% and it was 25&#x000a0;% for placebo. Adverse events (AEs) emerging from the treatment were reported by 22&#x000a0;% of the patients receiving placebo and by 65, 73, 87 and 87&#x000a0;% of patients receiving 50, 100, 200 and 400&#x000a0;mg, respectively. The majority of AEs after lasmiditan 100 and 400&#x000a0;mg were moderate or severe. For the understanding of migraine pathophysiology, it is very important to note that a selective 5-HT<sub>1F</sub> receptor agonist like lasmiditan is effective in the acute treatment of migraine. Thus, migraine can be treated with a drug that has no vasoconstrictor ability. While lasmiditan most likely is effective in the treatment of migraine attacks it had, unfortunately, a high incidence of CNS related AEs in the oral RCT. If confirmed in larger studies in phase III, this might adversely limit the use of this highly specific non-vascular acute treatment of migraine. Larger studies including the parameters of patients&#x02019; preferences are necessary to accurately position this new treatment principle in relation to the triptans.</p></abstract><kwd-group><title>Keywords</title><kwd>Lasmiditan</kwd><kwd>5-HT<sub>1F</sub> receptor agonism</kwd><kwd>Migraine</kwd><kwd>Randomised controlled trial</kwd><kwd>Phase II</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2012</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>The pathophysiology of migraine is incompletely understood. Previously, extracranial dilatation was considered pivotal in causing migraine headache [<xref ref-type="bibr" rid="CR1">1</xref>]. The selective 5-HT<sub>1B/1D</sub> receptor agonists, triptans, were developed as relatively selective cranial vasoconstrictors based on the efficacy on the 5-HT<sub>1B</sub> receptor [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. This receptor is also present in non-cranial vasculature [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] and the triptans carry the risk of causing coronary vasoconstriction [<xref ref-type="bibr" rid="CR4">4</xref>]. The triptans are thus contraindicated in patients with cardio- and cerebrovascular disease. The CGRP antagonists, olcegepant [<xref ref-type="bibr" rid="CR6">6</xref>], telcagepant [<xref ref-type="bibr" rid="CR7">7</xref>], BI 44370 TA [<xref ref-type="bibr" rid="CR8">8</xref>] and MK-3207 [<xref ref-type="bibr" rid="CR9">9</xref>] were developed for migraine as drugs devoid of general vasoconstrictor activity [<xref ref-type="bibr" rid="CR10">10</xref>]. They were effective in the acute treatment of migraine [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], but the developments were stopped for various reasons [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>It has been suggested that cranial vasodilatation, observed previously [<xref ref-type="bibr" rid="CR12">12</xref>] and quite recently [<xref ref-type="bibr" rid="CR13">13</xref>], is not the primary nociceptive stimulus for migraine headache [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], and that neural inhibition of trigeminal pathways could provide an alternative non-vascular antimigraine mechanism [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec2"><title>Preclinical pharmacological profile of lasmiditan [<xref ref-type="bibr" rid="CR16">16</xref>]</title><p>In vitro binding studies of lasmiditan showed a <italic>K</italic><sub>i</sub> value of 2.2&#x000a0;nM at the 5-HT<sub>1F</sub> receptor, compared with <italic>K</italic><sub>i</sub> values of 1,043 and 1,357&#x000a0;nM at the 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors, respectively, which is a selectivity ratio &#x0003e;470-fold [<xref ref-type="bibr" rid="CR16">16</xref>]. Unlike sumatriptan, a 5-HT<sub>1B/1D</sub> receptor agonist, lasmiditan did not contract rabbit saphenous vein rings at concentrations up to 100&#x000a0;&#x003bc;M [<xref ref-type="bibr" rid="CR16">16</xref>]. In two rodents models with presumed relevance for migraine (dural plasma extravasation, and induction of the immediate early gene <italic>c</italic>-<italic>Fos</italic> in the trigeminal nucleus caudalis), oral administration of lasmiditan potently inhibited these markers associated with electrical stimulation of the trigeminal ganglion [<xref ref-type="bibr" rid="CR16">16</xref>]. The oral bioavailability of lasmiditan is 40&#x000a0;% and the <italic>T</italic><sub>max</sub> is 2&#x000a0;h (CoLucid Pharmaceuticals, data on file).</p></sec><sec id="Sec3"><title>Review of phase II trials</title><p>Lasmiditan has so far been investigated in two RCTs: one with intravenous [<xref ref-type="bibr" rid="CR15">15</xref>], and one with oral administration [<xref ref-type="bibr" rid="CR17">17</xref>] of the drug.</p><p>The intravenous RCT was a randomised, multicentre, double-blind, placebo-controlled, group-sequential, adaptive treatment-assignment, proof-of-concept and dose-finding study [<xref ref-type="bibr" rid="CR15">15</xref>]. The investigators treated 130 in-hospital migraine patients with moderate or severe headache. The patients were allocated to a range of intravenous dose levels of lasmiditan or placebo in small cohorts (<italic>n</italic>&#x000a0;=&#x000a0;5&#x02013;6). The starting dose was 2.5&#x000a0;mg. Subsequent doses were adjusted up and down according to the efficacy and safety observed in the preceding cohort. The primary efficacy measure was headache relief (a decrease in headache from moderate or severe to none or mild) at 2&#x000a0;h.</p><p>A total of 88 patients received lasmiditan in doses of 2.5&#x02013;45&#x000a0;mg, and 42 received placebo. The study was terminated when the 20&#x000a0;mg dose met predefined efficacy stopping rules [<xref ref-type="bibr" rid="CR15">15</xref>]. As illustrated in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> there was a linear association between response rates and dose level (<italic>P</italic>&#x000a0;=&#x000a0;0.0126) [<xref ref-type="bibr" rid="CR15">15</xref>]. For lasmiditan 20&#x000a0;mg, the headache relief was 64&#x000a0;% and for placebo it was 45&#x000a0;%. Thus, the therapeutic gain (percentage difference between active drug and placebo) was 19&#x000a0;% (95&#x000a0;% CI &#x02212;4 to 42&#x000a0;%). Adverse events were generally mild and were reported by 65&#x000a0;% of patients on lasmiditan and 43&#x000a0;% on placebo [<xref ref-type="bibr" rid="CR15">15</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Proportion of migraine patients with headache relief (a decrease of headache from moderate or severe to none or mild) (HR) at 2&#x000a0;h after intravenous lasmiditan (<italic>PBO</italic> placebo) [<xref ref-type="bibr" rid="CR15">15</xref>]</p></caption><graphic xlink:href="10194_2012_428_Fig1_HTML" id="MO1"/></fig></p><p>The oral RCT with lasmiditan was a randomised, double-blind, placebo-controlled, parallel-group study [<xref ref-type="bibr" rid="CR17">17</xref>]. Patients were randomized to oral lasmiditan (50, 100, 200 or 400&#x000a0;mg) or placebo in a 1:1:1:1.1 ratio. Out of 534 screened and randomized patients, 391 treated a migraine attack and 378 patients qualified for the primary modified intent-to-treat analysis [<xref ref-type="bibr" rid="CR17">17</xref>]. Patients treated moderate or severe migraine headache, and the primary efficacy measure was headache relief (HR) 2&#x000a0;h after drug administration (see Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>; Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Headache response for all doses of lasmiditan was superior to placebo (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). For lasmiditan 400&#x000a0;mg, the therapeutic gain was 38&#x000a0;% (95&#x000a0;% CI 28&#x02013;51&#x000a0;%) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Adverse events emerging from the treatment were reported by 22&#x000a0;% of the patients receiving placebo and by 65, 73, 87 and 87&#x000a0;% of patients receiving 50, 100, 200 and 400&#x000a0;mg lasmiditan, respectively [<xref ref-type="bibr" rid="CR17">17</xref>]. The AEs for placebo and lasmiditan 100 and 400&#x000a0;mg are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The distribution of intensity of AEs after placebo and oral lasmiditan 100 and 400&#x000a0;mg is shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. The majority of AEs after placebo were mild (15&#x000a0;%) or moderate (13&#x000a0;%), whereas the majority of AEs after lasmiditan were moderate [46&#x000a0;% (100&#x000a0;mg), 60&#x000a0;% (400&#x000a0;mg)] or severe [27&#x000a0;% (100&#x000a0;mg), 44&#x000a0;% (400&#x000a0;mg)] [CoLucid Pharmaceuticals, data on file].<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Proportion of migraine patients with HR at 2&#x000a0;h after oral lasmiditan 50&#x02013;400&#x000a0;mg (<italic>PBO</italic> placebo). *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 [<xref ref-type="bibr" rid="CR17">17</xref>]</p></caption><graphic xlink:href="10194_2012_428_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Headache relief after intravenous and oral lasmiditan, subcutaneous and oral sumatriptan, and oral LY334370 in randomised, clinical trials (RCTs) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Drug</th><th align="left">Headache relief for active drug at 2&#x000a0;h (%)</th><th align="left">Headache relief for placebo at 2&#x000a0;h (%)</th><th align="left">Therapeutic gain (95&#x000a0;% confidence intervals) (%)</th><th align="left">NNT (number needed to treat)</th></tr></thead><tbody><tr><td align="left">Intravenous lasmiditan 20&#x000a0;mg [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td char="." align="char">64</td><td char="." align="char">45</td><td char="(" align="char">19 (&#x02212;4 to 42&#x000a0;%)<sup>a</sup></td><td char="." align="char">5.3</td></tr><tr><td align="left">Oral lasmiditan 400&#x000a0;mg [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td char="." align="char">64</td><td char="." align="char">25</td><td char="(" align="char">38 (28 to 51&#x000a0;%)</td><td char="." align="char">2.6</td></tr><tr><td align="left">Subcutaneous sumatriptan 6&#x000a0;mg [<xref ref-type="bibr" rid="CR7">7</xref>]</td><td char="." align="char">69</td><td char="." align="char">19</td><td char="(" align="char">51 (48 to 53&#x000a0;%)</td><td char="." align="char">2.0</td></tr><tr><td align="left">Oral sumatriptan 100&#x000a0;mg [<xref ref-type="bibr" rid="CR7">7</xref>]</td><td char="." align="char">61</td><td char="." align="char">28</td><td char="(" align="char">33 (31 to 35&#x000a0;%)</td><td char="." align="char">3.0</td></tr><tr><td align="left">LY334370 200&#x000a0;mg [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td char="." align="char">71</td><td char="." align="char">19</td><td char="(" align="char">52 (27 to 77&#x000a0;%)</td><td char="." align="char">2.0</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The RCT did not have the power to compare the single doses of lasmiditan with placebo</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Adverse events with an incidence &#x0003e;5&#x000a0;% of patients in any dose group [<xref ref-type="bibr" rid="CR17">17</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Adverse event</th><th align="left">Placebo (%)</th><th align="left">Lasmiditan 100&#x000a0;mg (%)</th><th align="left">Lasmiditan 400&#x000a0;mg (%)</th></tr></thead><tbody><tr><td align="left">Dizziness</td><td char="." align="char">1</td><td char="." align="char">28</td><td char="." align="char">37</td></tr><tr><td align="left">Fatigue</td><td char="." align="char">2</td><td char="." align="char">21</td><td char="." align="char">24</td></tr><tr><td align="left">Vertigo</td><td char="." align="char">1</td><td char="." align="char">15</td><td char="." align="char">24</td></tr><tr><td align="left">Somnolence</td><td char="." align="char">2</td><td char="." align="char">12</td><td char="." align="char">11</td></tr><tr><td align="left">Paraesthesia</td><td char="." align="char">2</td><td char="." align="char">11</td><td char="." align="char">20</td></tr><tr><td align="left">Heaviness</td><td char="." align="char">1</td><td char="." align="char">5</td><td char="." align="char">7</td></tr><tr><td align="left">Nausea</td><td char="." align="char">0</td><td char="." align="char">11</td><td char="." align="char">7</td></tr></tbody></table></table-wrap><table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Adverse events by intensity after placebo and oral lasmiditan 100 and 400&#x000a0;mg (CoLucid Pharmaceuticals, data on file)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Intensity of adverse events</th><th align="left">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;86)</th><th align="left">Lasmiditan 100&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;82)</th><th align="left">Lasmiditan 400&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;70)</th></tr></thead><tbody><tr><td align="left">Mild</td><td char="(" align="char">14 (16&#x000a0;%)</td><td char="(" align="char">35 (43&#x000a0;%)</td><td char="(" align="char">21(30&#x000a0;%)</td></tr><tr><td align="left">Moderate</td><td char="(" align="char">11 (13&#x000a0;%)</td><td char="(" align="char">38 (46&#x000a0;%)</td><td char="(" align="char">42 (60&#x000a0;%)</td></tr><tr><td align="left">Severe</td><td char="(" align="char">5 (6&#x000a0;%)</td><td char="(" align="char">22 (27&#x000a0;%)</td><td char="(" align="char">31 (44&#x000a0;%)</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4" sec-type="discussion"><title>Discussion</title><p>The intravenous randomised controlled trial of lasmiditan [<xref ref-type="bibr" rid="CR15">15</xref>] should be considered as a proof-of-concept study validating the principle of 5-HT<sub>1F</sub> receptor agonism in the acute treatment of migraine. It was not powered to demonstrate superiority of the individual doses of lasmiditan to placebo (see Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The oral study [<xref ref-type="bibr" rid="CR17">17</xref>] documented beyond doubt that 5-HT<sub>1F</sub> agonism is highly effective (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>), perhaps as effective as the triptans. Usually one would expect an intravenous administration of a drug to be more effective and cause more adverse events (AEs) than the oral form of the drug. With lasmiditan, the case was the opposite: oral administration is better than the intravenous administration as judged from the therapeutic gains which were 38 and 19&#x000a0;%, respectively (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The reason for these results is most likely a relatively low intravenous dose of 20&#x000a0;mg lasmiditan. The oral dose of lasmiditan was 400&#x000a0;mg and the oral bioavailability of lasmiditan is 40&#x000a0;% (CoLucid Pharmaceuticals, data on file). Thus, an oral dose of 400&#x000a0;mg corresponds to an intravenous dose of 160&#x000a0;mg far above the doses (2.5&#x02013;45&#x000a0;mg) used in the intravenous RCTs. A high placebo response with intravenous treatment may, however, also diminish the TG. Therefore, the absolute response is also important and for oral lasmiditan it was similar to previous results with oral triptans.</p><p>Adverse events should also be evaluated by their absolute size and by subtracting the AEs after placebo from AEs after active drug. For oral lasmiditan 400&#x000a0;mg, the placebo-subtracted AEs rate is 62&#x000a0;% [number needed to harm (NNH) 1.6]. For intravenous lasmiditan 20&#x000a0;mg the placebo-subtracted AEs is 25&#x000a0;% (NNH 4). Thus, oral lasmiditan 400&#x000a0;mg caused more AEs than the intravenous dose of 20&#x000a0;mg as would be expected from the higher dose absorbed with the oral 400&#x000a0;mg dose. For the standard triptan, sumatriptan 100&#x000a0;mg, the placebo-subtracted AEs rate is 16&#x000a0;% (NNH 6.3) [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>The high incidence of AEs for lasmiditan is of potential concern, but needs further evaluation due to small numbers. In future RCTs, one should include also a global evaluation of study medication, such as excellent, very good, good, neither good nor bad, poor, very poor and extremely poor [<xref ref-type="bibr" rid="CR8">8</xref>]. This would allow an estimation of how patients really rate the recorded adverse events.</p><p>The results seem to suggest that a dose of 100&#x000a0;mg might be preferable to 400&#x000a0;mg because apparently it had the same efficacy in terms of headache relief (see Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). This would, however, only result in a minor decrease in AEs to 73&#x000a0;%. Paradoxically, the pain-free response at 2&#x000a0;h was considerably smaller with 100 than with 400&#x000a0;mg. If this is real and not just due to statistical fluctuation, pain-free response would decrease from 28 (lasmiditan 400&#x000a0;mg) to 14&#x000a0;% (lasmiditan 100&#x000a0;mg) [<xref ref-type="bibr" rid="CR17">17</xref>]. Migraine patients want to be pain free [<xref ref-type="bibr" rid="CR19">19</xref>] and 14&#x000a0;% pain free is too low for a drug to be successful in our opinion. Again, more studies with higher numbers are necessary to answer these questions.</p><p>The effect of intravenous lasmiditan should be compared to the current standard triptan, sumatriptan, as illustrated in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The therapeutic gain (TG) (percentage difference between active drug and placebo) for intravenous lasmiditan 20&#x000a0;mg was 19&#x000a0;% (95&#x000a0;% CI &#x02212;4 to 42&#x000a0;%) and it was 51&#x000a0;% (95&#x000a0;% CI 48&#x02013;53&#x000a0;%) for subcutaneous sumatriptan 6&#x000a0;mg [<xref ref-type="bibr" rid="CR18">18</xref>]. This lower response for intravenous lasmiditan compared with subcutaneous sumatriptan probably reflects the low dose of intravenous lasmiditan.</p><p>The oral administration of lasmiditan 400&#x000a0;mg should be compared to the standard triptan, sumatriptan 100&#x000a0;mg, and the previously investigated 5-HT<sub>1F</sub> receptor agonist LY334370 200&#x000a0;mg [<xref ref-type="bibr" rid="CR19">19</xref>]. The TG for lasmiditan (<italic>n</italic>&#x000a0;=&#x000a0;156) was 38&#x000a0;% (95&#x000a0;% CI 28&#x02013;51&#x000a0;%) comparable to the TG of 33&#x000a0;% (95&#x000a0;% CI 31&#x02013;35&#x000a0;%) for oral sumatriptan (<italic>n</italic>&#x000a0;=&#x000a0;5,072) [<xref ref-type="bibr" rid="CR18">18</xref>]. The TG for 5-HT<sub>1F</sub> receptor agonist LY334370 200&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;47) was 52&#x000a0;% (95&#x000a0;% CI 27&#x02013;77&#x000a0;%) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR20">20</xref>] and apparently higher than the two other oral drugs. However, as few patients were included in RCTs of lasmiditan and LY334370 resulted in very wide confidence intervals; therefore, superiority as compared with sumatriptan should not be claimed.</p><p>For the understanding of migraine pathophysiology, it is very important to note that a selective 5-HT<sub>1F</sub> receptor agonist like lasmiditan is effective in the acute treatment of migraine. This is supported by the previous results with the other 5-HT<sub>1F</sub> receptor agonist, LY333470 [<xref ref-type="bibr" rid="CR20">20</xref>] (see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Thus, migraine attacks can be treated with a drug that has no vasoconstrictor ability (it remains to be seen if vasoconstriction of vessels dilated because of a migraine attack does occur). The 5-HT<sub>1F</sub> effect may take place at the perivascular trigeminal nerve terminals, which will be stabilized and less likely to leak vasoactive and potentially nociceptive signalling molecules. However, Burstein&#x02019;s group has shown that this mechanism is unimportant with the triptans which rather seem to work by blocking nociceptive transmission at the first synapse in the trigeminal nucleus caudalis [<xref ref-type="bibr" rid="CR21">21</xref>]. It seems likely that the same is the case for 5-HT<sub>1F</sub> receptor agonists. Seemingly, this would support the neural theory of migraine [<xref ref-type="bibr" rid="CR14">14</xref>]. However, blocking the trigeminovascular system would also be effective if peripheral nociception was the primary cause of headache [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p>In conclusion, the 5-HT<sub>1F</sub> receptor agonist lasmiditan is effective in the acute treatment of migraine. Unfortunately, it has a high incidence of CNS-related side effects. If confirmed in larger studies, this might adversely affect the uptake of this highly specific non-vascular acute treatment. Larger studies including the parameters of patients&#x02019; preferences are necessary to accurately position this new treatment principle in relation to the triptans.</p></sec></body><back><ack><title>Conflict of interest</title><p>Jes Olesen has within the last 2&#x000a0;years received grants/research support from and/or has been a consultant/scientific advisor for, and/or has been on the speakers bureau of Merck and Company, UCB Pharma, Bristol-Myers-Squibb, NeurAxon, Zogenix and H. Lundbeck. Peer Tfelt-Hansen has no financial interest to disclose.</p><sec id="d29e896"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>HG</given-names></name></person-group><source>Headache and other head pain</source><year>1963</year><publisher-loc>New York</publisher-loc><publisher-name>University Press</publisher-name></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>PP</given-names></name><name><surname>Feniuk</surname><given-names>W</given-names></name><name><surname>Perren</surname><given-names>MJ</given-names></name><name><surname>Beresford</surname><given-names>IJ</given-names></name><name><surname>Skingle</surname><given-names>M</given-names></name><name><surname>Whalley</surname><given-names>ET</given-names></name></person-group><article-title>Serotonin and migraine</article-title><source>Ann N Y Acad Sci</source><year>1990</year><volume>600</volume><fpage>587</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1990.tb16912.x</pub-id><pub-id pub-id-type="pmid">2252337</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name><name><surname>Vries</surname><given-names>P</given-names></name><name><surname>Saxena</surname><given-names>PR</given-names></name></person-group><article-title>Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy</article-title><source>Drugs</source><year>2000</year><volume>60</volume><fpage>1259</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.2165/00003495-200060060-00003</pub-id><pub-id pub-id-type="pmid">11152011</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MaasenVanDenBrink</surname><given-names>A</given-names></name><name><surname>Reekers</surname><given-names>M</given-names></name><name><surname>Bax</surname><given-names>WA</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name><name><surname>Saxena</surname><given-names>PR</given-names></name></person-group><article-title>Coronary side-effect potential of current and prospective antimigraine drugs</article-title><source>Circulation</source><year>1998</year><volume>98</volume><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">9665056</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name><name><surname>Seidelin</surname><given-names>K</given-names></name><name><surname>Stepanavage</surname><given-names>M</given-names></name><name><surname>Lines</surname><given-names>C</given-names></name></person-group><article-title>The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects</article-title><source>Br J Clin Pharmacol</source><year>2002</year><volume>54</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2002.01403.x</pub-id><pub-id pub-id-type="pmid">12100223</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Husstedt</surname><given-names>IW</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Hall</surname><given-names>D</given-names></name><name><surname>Meier</surname><given-names>U</given-names></name><etal/></person-group><article-title>Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for acute treatment of migraine</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>1104</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030505</pub-id><pub-id pub-id-type="pmid">15014183</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name></person-group><article-title>Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine</article-title><source>Headache</source><year>2011</year><volume>51</volume><fpage>118</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2010.01797.x</pub-id><pub-id pub-id-type="pmid">21070229</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Barbanti</surname><given-names>P</given-names></name><name><surname>Dahl&#x000f6;f</surname><given-names>C</given-names></name><name><surname>Reuter</surname><given-names>U</given-names></name><name><surname>Habeck</surname><given-names>J</given-names></name><name><surname>Podhorna</surname><given-names>J</given-names></name></person-group><article-title>BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study</article-title><source>Cephalalgia</source><year>2011</year><volume>31</volume><fpage>573</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1177/0333102410388435</pub-id><pub-id pub-id-type="pmid">21172952</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>DJ</given-names></name><name><surname>Aurora</surname><given-names>SK</given-names></name><name><surname>Dodick</surname><given-names>DW</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Ge</surname><given-names>YJ</given-names></name><name><surname>Bachman</surname><given-names>R</given-names></name><etal/></person-group><article-title>Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine</article-title><source>Cephalalgia</source><year>2011</year><volume>31</volume><fpage>712</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1177/0333102411398399</pub-id><pub-id pub-id-type="pmid">21383045</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villal&#x000f5;n</surname><given-names>CM</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group><article-title>The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs</article-title><source>Pharmacol Ther</source><year>2009</year><volume>124</volume><fpage>309</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2009.09.003</pub-id><pub-id pub-id-type="pmid">19796656</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Tfelt-Hansen PC (2012) Current understanding of calcitonin gene-related peptide (CGRP) in relation to both migraine pathophysiology and therapy. Exp Rev Neurother (in press)</mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>JR</given-names></name><name><surname>Wolff</surname><given-names>HG</given-names></name></person-group><article-title>Mechanism of migraine headache and the action of ergotamine tartrate</article-title><source>Arch Neurol Psychiatr</source><year>1938</year><volume>39</volume><fpage>737</fpage><lpage>763</lpage></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asghar</surname><given-names>MS</given-names></name><name><surname>Hansen</surname><given-names>AE</given-names></name><name><surname>Amin</surname><given-names>FM</given-names></name><name><surname>Geest</surname><given-names>RJ</given-names></name><name><surname>Koning</surname><given-names>P</given-names></name><name><surname>Larsson</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Evidence for a vascular factor in migraine</article-title><source>Ann Neurol</source><year>2011</year><volume>69</volume><fpage>635</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1002/ana.22292</pub-id><pub-id pub-id-type="pmid">21416486</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Charbit</surname><given-names>AR</given-names></name><name><surname>Andreou</surname><given-names>AP</given-names></name><name><surname>Akerman</surname><given-names>S</given-names></name><name><surname>Holland</surname><given-names>PR</given-names></name></person-group><article-title>Neurobiology of migraine</article-title><source>Neuroscience</source><year>2009</year><volume>161</volume><fpage>327</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.03.019</pub-id><pub-id pub-id-type="pmid">19303917</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>MD</given-names></name><name><surname>F&#x000e4;rkkil&#x000e4;</surname><given-names>M</given-names></name><name><surname>Reuter</surname><given-names>U</given-names></name><name><surname>Pilgrim</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>C</given-names></name><name><surname>Krauass</surname><given-names>M</given-names></name><collab>For the European COL-144 Investigators</collab></person-group><article-title>Acute treatment of migraine with the selective 5-HT<sub>1F</sub> receptor agonist lasmiditan&#x02014;a randomised proof-of-concept trial</article-title><source>Cephalalgia</source><year>2010</year><volume>30</volume><fpage>1170</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1177/0333102410375512</pub-id><pub-id pub-id-type="pmid">20855362</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>DL</given-names></name><name><surname>Phebus</surname><given-names>LA</given-names></name><name><surname>Johnson</surname><given-names>KW</given-names></name><name><surname>Wainscott</surname><given-names>DB</given-names></name><name><surname>Cohen</surname><given-names>ML</given-names></name><name><surname>Calligaro</surname><given-names>DO</given-names></name><etal/></person-group><article-title>Preclinical pharmacological profile of the selective 5-HT<sub>1F</sub> receptor agonist lasmiditan</article-title><source>Cephalalgia</source><year>2010</year><volume>30</volume><fpage>1159</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1177/0333102410370873</pub-id><pub-id pub-id-type="pmid">20855361</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>F&#x000e4;kkil&#x000e4;</surname><given-names>M</given-names></name><name><surname>Diener</surname><given-names>H-C</given-names></name><name><surname>G&#x000e9;raud</surname><given-names>G</given-names></name><name><surname>L&#x000e1;niz</surname><given-names>JM</given-names></name><name><surname>Schoenen</surname><given-names>J</given-names></name><name><surname>Pilgrim</surname><given-names>AJ</given-names></name></person-group><article-title>Lasmiditan (COL-144), a selective 5HT1F agonist, is a rapid and effective oral treatment for acute migraine</article-title><source>J Headache Pain</source><year>2010</year><volume>11</volume><issue>Suppl 1</issue><fpage>S43</fpage></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>PR</given-names></name><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name><name><surname>Ramadan</surname><given-names>NM</given-names></name><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name><name><surname>Welch</surname><given-names>KMA</given-names></name></person-group><article-title>Triptans, 5HT1B/1D agonists in the acute treatment of migraine</article-title><source>The headaches</source><year>2006</year><edition>3</edition><publisher-loc>Philadelphia</publisher-loc><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><fpage>469</fpage><lpage>503</lpage></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Hamelsky</surname><given-names>SW</given-names></name><name><surname>Dayno</surname><given-names>JM</given-names></name></person-group><article-title>What do patients with migraine want from acute migraine treatment?</article-title><source>Headache</source><year>2002</year><volume>42</volume><issue>Suppl 1</issue><fpage>S3</fpage><lpage>S9</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2002.0420s1003.x</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>DJ</given-names></name><name><surname>Roon</surname><given-names>KI</given-names></name><name><surname>Offen</surname><given-names>WW</given-names></name><name><surname>Ramadan</surname><given-names>NM</given-names></name><name><surname>Phebus</surname><given-names>LA</given-names></name><name><surname>Johnson</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Selective serotonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomized controlled trial</article-title><source>Lancet</source><year>2001</year><volume>38</volume><fpage>1230</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(01)06347-4</pub-id><pub-id pub-id-type="pmid">11675061</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Jakubowski</surname><given-names>M</given-names></name><name><surname>Burstein</surname><given-names>R</given-names></name></person-group><article-title>Disruption of communication between peripheral and central trigeminovascular neurons mediates the action of 5HT1B/1D receptor agonists</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>4274</fpage><lpage>4279</lpage><pub-id pub-id-type="doi">10.1073/pnas.0306147101</pub-id><pub-id pub-id-type="pmid">15016917</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Burstein</surname><given-names>R</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name></person-group><article-title>Origin of pain (nociception) in migraine</article-title><source>Lancet Neurol</source><year>2009</year><volume>8</volume><fpage>679</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(09)70090-0</pub-id><pub-id pub-id-type="pmid">19539239</pub-id></mixed-citation></ref></ref-list></back></article>